Rash in an HIV-positive patient

HIV Medicine

Volumn 6, Issue 6, 2005, Pages 379-

  Herzmann, Christian ^a   Kinloch, S ^a   Johnson, M ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; CASE REPORT; DIARRHEA; DRUG HYPERSENSITIVITY; ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; RASH; REVIEW;

ADULT; DRUG ERUPTIONS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; OLIGOPEPTIDES; PYRIDINES;

EID: 28444485255     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00329.x     Document Type: Review

References (3)

1. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
2. Sanne I, Piliero P, Squires K et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immun Defic Syndr 2003; 32: 18-29.
3. Haas DW, Zala C, Schrader S et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003; 17: 1339-1349.